Shruti Bhat PhD, MBA, Lean Six Sigma Black Belt
  • Home
  • About Shruti
  • Consulting
  • Workshops
  • Patents
  • Articles
    • Case Studies
    • Innovation Portfolio Development & Patents
    • Drugs-in-the- making
    • Culture Change & Business Transformation
    • Operational Excellence, Quality & Continuous Improvement
  • Books
  • Digital
  • Blog
  • Videos
  • Contact

Quality Control & Regulatory Requirements of Controlled Release Drug Delivery Systems.

5/18/2009

0 Comments

 
Quality parameters such as assay, content uniformity, and dissolution rate test along with the already established destructive & non-destructive tests for physical parameters need to be carried out for the controlled release systems as well.  

In order to gain FDA approval of New Drug Application for a new chemical entity initially marketed in Controlled Release Dosage forms (as with all other similar products), clinical studies in patients establishing the safety and efficacy of each particular dosage form are required.  

For drugs that have been previously approved as safe and effective in controlled release dosage forms, data are required to establish bioavailability / bioequivalence to an approved controlled release drug product. Single dose bioavailability studies are acceptable for determining the fraction of the amount absorbed, lack of dose dumping, lack of food effects etc.  

Pharmacokinetic studies, performed under steady-state conditions are acceptable to demonstrate comparability to an approved immediate release drug product, occupancy time within a therapeutic window, percent fluctuation etc.  The specific types of in-vivo studies include:


  • Fasted single dose studies
  • Post prandial study
  • Multiple dose steady-state studies. 


Regulatory Considerations for Specialized CRDDS:

Novel CRDDS evolved in recent years viz. Ocusert, Oros, Copper and Progesterone releasing IUD’s and transdermal systems are considered new drugs requiring full new drug applications (NDA) as a basis of drug approval. In addition to safety and efficacy considerations which includes an understanding of the drug input function, plasma blood level oscillation and the drug’s pharmacodynamics, there are biopharmaceutic and pharmacodynamic issues that need to be addressed by the manufacturer such as :
​
  1. Reproductivity of the new drug delivery system by in-vivo or in vitro studies.
  2. A defined bioavailability profile which rules out dose dumping.
  3. Demonstration of reasonably good absorption relative to an appropriate standard and     which considers important elements e.g. obviating of first pass gut or liver metabolism.
  4. A well-defined pharmacokinetic profile to support drug labeling.
  5. In vitro characterization (when possible).
Follow Shruti on Twitter, Facebook, YouTube, LinkedIn
0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    Shruti Bhat, global leader in business turnaround, operational excellence and continuous improvement

    New Book Released!

    top ten strategic decision-making tools for operational excellence

    Shruti's YouTube Channel ...

    Picture

    Blog Categories

    All
    3D Printing
    5S
    Agile
    Artificial Intelligence
    Automation
    Balanced Score Card
    Biotechnology
    Books
    Business Turnaround
    Case Studies
    Change Management
    Chemical Industry
    CMMI
    Continuous Improvement
    Design Thinking
    Digitalization
    Drug Delivery
    External News Links
    Food Industry
    Hall Of Fame
    Healthcare
    Hoshin Kanri
    HR Development
    Innovation
    ISO
    Just In Time
    Kaizen
    Leadership
    LEAN
    Lean Six Sigma
    Life Sciences
    Machine Learning
    Manufacturing
    Medical Devices
    Mistake Proofing
    Motivational Cards
    Nanotechnology
    Operations
    Packaging
    Patents
    Personal Products
    Process Improvement
    Product Development
    Productivity Increase
    QbD
    Quality Management
    Robotics
    Scrum
    Service Industry
    Six Sigma
    Strategy
    Supply Chain Logistics
    Telecom Industry
    TQM
    Videos
    Voice Of Customer
    Workshops

    Shruti's books...

    Picture
    shruti bhat, business process management, continuous improvement
    kaizen for pharmaceutcials, medical devices and biotech industry book by Dr Shruti Bhat
    Book on Continuous improvement tools by Dr Shruti Bhat
    kaizen for leaders, continuous process improvement tool to increase profit and organizational excellence by shruti bhat
    kaizen, shruti bhat, continuous improvement, quality, operations management
    Picture
    how to overcome challenges of creating effective teams
    how to lead a successful business transformation

    ​Micro-Learning
    ​Partner

    Picture

    Publishing Partner

    fast read books, business management books, health and wellness books, spiritual guidance books, best online book store

    Wellness
    ​Partner

    Picture
© Copyright 1992- 2022 Dr. Shruti Bhat ALL RIGHTS RESERVED.
See Terms and Conditions for details on this site usage.
SHRUTI BHAT, CONTACT
Click to connect.
Created by Macro2Micro Media